<DOC>
	<DOCNO>NCT00635713</DOCNO>
	<brief_summary>The main purpose study compare effect 2 dos FASLODEX 1 dose ARIMIDEX term time tumor progression postmenopausal woman advance breast cancer .</brief_summary>
	<brief_title>Second Line Breast Cancer Trial</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>postmenopausal woman confirmation breast cancer objective evidence recurrence progression breast cancer 1 prior hormonal therapy breast cancer presence lifethreatening metastatic visceral disease previous treatment FASLODEX , ARIMIDEX aromatase inhibitor breast cancer 1 prior endocrine medical treatment advance breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Advanced breast cancer , FASLODEX , ARIMIDEX , Fulvestrant , Anastrozole , postmenopausal</keyword>
</DOC>